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4 Introduction 
4.1 Describing consumption of antibacterial agents 
Antibacterial agents are among the most frequently used drugs worldwide, and 
contribute immensely to human and animal health. However, the consumption of 
antibacterial agents is closely linked to emergence and spread of resistance in 
commensal and pathogenic species (1, 2). A high prevalence of resistance in human 
pathogens is associated with a detrimental outcome and increased costs in the 
treatment of infectious diseases (3). Mathematical modeling and epidemiological 
observations suggest that the emergence of resistance caused by constant selective 
pressure from antibacterial agents evolves more rapidly compared to the decay time 
after a decline in the consumption (4, 5). The rational use of antibacterial agents is 
increasingly recognized as an important contribution to control the worldwide 
emergence of bacterial resistance, to minimize side effects and to reduce the cost of 
treatment (6-8). Knowledge on how antibacterial agents are being prescribed and used 
is fundamental to obtain rational drug use. Information of the past performance of 
prescribers and consumers is the pillar in all auditing systems (9). Consumption of 
antibacterial agents can be described at an ecological level, where information on the 
identity of the consumer and individual consumption is unavailable, or at an individual 
level where such information is assessed.  
 
The ecological level 
The concept of describing consumption of antibacterial agents at an ecological level 
must address; i) the profile of therapy, ii) the extent of consumption, and iii) the trends 
in consumption over time. The profile of therapy is precisely described by using the 
International Non-proprietary Name (INN), which is a unique and internationally 
recognized identification of an active pharmaceutical substance. Non-proprietary 
names are public property, and are synonymous to generic names (10).  
To describe the extent of consumption is a more complex exercise, with several 
nominators and denominators available. In addition, it is also necessary to consider 
consumption among outpatients differently from consumption in hospitals or other 
variants of institutional care.  
 
Outpatients consume approximately 85 - 93% of the total volume of antibacterial 
agents, a proportion which depends on the organization of health care services and the 
availability of institutional health care on national level (11, 12). The consumption 
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among outpatients has been expressed in physical units (mass or volume), the number 
of packages, tablets or ampoules, the proportion of prescriptions with antibacterial 
agents, the number of patient’s days on an estimated clinical dose, or as a defined 
daily dose (DDD). The DDD for an active pharmaceutical substance is the average 
maintenance dose used for its major indication in adults (9). All units except the 
proportion of prescription with antibacterial agents are normally adjusted for the 
population under risk over a given time period, usually expressed per 
1000/inhabitants/day (DID). For some agents there is a considerable discrepancy 
between DDD and the actual clinical dose. The DID is therefore only a rough estimate 
of the proportion of the population under treatment. DDD’s are revised over time, 
necessitating recalculation of consumption data in time trend analysis when long time 
periods are considered. Divergent versions of the ATC/DDD system have been shown 
to cause methodological problems when comparing national consumptions (13). 
Despite several other limitations, the DID is the WHO recommended method for 
monitoring outpatient use of antibacterial agents. The trends in drug consumption are 
important sources of information, and can contribute to the understanding of changing 
drug costs, and possibly identify regional differences and suboptimal use of 
antibacterial agents. To uncover trends in the consumption of antibacterial drugs 
amongst outpatients requires access to longitudinal data, preferably collected over 
several years. For example, longitudinal data on the consumption of antibacterial 
agents in Norway show an increase over the last eight years (14). This increase can not 
be explained by changes in the panorama of infectious diseases, the prevalence of 
resistant strains, or the age structure of the population (15).   
 
In hospitals, the extent of consumption has been expressed in physical units per bed or 
per bed day for a given time period, or as DDD/100 bed days/year or DDD/100 
admissions/year, or as days of therapy per time period (DOT) (16-19). DDD adjusted 
for bed days has been the recommended method for monitoring hospital use of 
antimicrobial agents, but this denominator has limitations when the number of 
admissions per time unit or the average staying time in the hospital changes over time 
(17, 18). An increasing number of admissions will always result in increased 
consumption, especially if the rise in admissions parallels a higher frequency of 
invasive procedures. For example, the average consumption of antibacterial agents 
expressed as DDD/100 bed days/year in a selection of Dutch hospitals increased by 
24% to 62,2 DDD/100 bed days/year over the years 2002 – 2006. Over the same 
period the number of DDD/100 admissions/year remained almost constant; 336,5 in 
2002 versus 335,8 in 2006 (20). Neither denominator indicates the number of patients 
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or the proportion of patients receiving antimicrobial therapy, but both methods should 
be considered when assessing compliance to clinical guidelines.  
 
The individual level 
At the individual level, information on; i) indication, ii) the choice of therapy, iii) the 
dosage, iv) the duration of treatment, v) the route of administration, and vi) the timing 
of the treatment may be necessary to answer important clinical questions and to give 
correct interpretation of the data. Also in this context it is necessary to consider 
consumption among outpatients differently from consumption in hospitals or other 
variants of institutional care. 
 
For outpatients, access to longitudinal data is important in the development of quality 
indicators on medical treatment and in planning interventions to optimize drug use 
(21). Until 2004, there were no systematic collections of national data on individual 
drug consumption amongst outpatients in Norway. From the 1st of January 2004, all 
pharmacies have been obliged to submit data to the Norwegian Prescription Database 
(NorPD) (22). The identity of the patient is encrypted, but a unique identifier derived 
from the Central Population Registry (CPR) enables the tracking of all prescriptions to 
a patient over time. Prescription databases are also established in the other Nordic 
countries, although with different possibilities to extract longitudinal data for 
individuals. Similar entities are not established in other parts of the world. Other 
sources of individual drug consumption amongst outpatients are interviews or 
questionnaires as parts of population based health surveys. Comprehensive surveys 
may also contain valuable information on clinical data, risk factors, and other 
variables that are associated with the consumption of antibacterial agents. However, 
these data sources can never be a substitution for a national prescription database 
decreed by law. 
 
In hospitals, the patient journal should ideally contain all relevant data on drug 
consumption, but such data are not always available (own observation, unpublished). 
In addition such data are readily accessible only if the complete journal is in electronic 
format, but electronic patient journals with information on drug consumption are not 
common in the Nordic countries. Access to data describing both individual 
consumption of antibacterial agents and resistance emergence in the bacterial 
pathogen infecting the same individual will provide a better understanding of the 
temporal relationship between consumption and resistance (16, 23).  
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4.2 Consumption of antibacterial agents – regional and national 
differences 
Systematic data on the profile and extent of use of antimicrobial agents at the national 
level is publicly and easily available only in a few developed countries and are scarce 
or non-existing in most developing countries. Possible sources of information on 
national use are reimbursement data based on financial claims from legitimate 
beneficiaries, from prescribers or pharmacies, or sales data from pharmaceutical 
companies, wholesalers, pharmacies or marketing research companies. The validity of 
such data may be affected by coverage bias in census data, sampling bias in sample 
data, unaccounted sales over the counter in reimbursement data, parallel trade, 
erroneous registration of non-reimbursed sale, and bias due to a mix of antibiotic use 
between hospital and ambulatory care (24-28). Most longitudinal data addressing 
consumption of antibacterial agents at a national level is aggregated and gives no 
information on individual consumption or how consumption is distributed over age 
groups. 
There is an abundance of data addressing regional differences within countries in 
choice of antibacterial therapy and the extent of consumption for outpatients, and also 
for differences between hospitals with similar patient populations (29-36). Most of 
these studies are descriptive and are thus unsuitable to elucidate the causal factors 
behind the observations.  
 
North-America, Canada and Australia 
The consumption in USA (25,5 DID) is higher than the average consumption in 
Europe, and there is a trend towards an earlier shift to newer agents in the USA (37). It 
is highly probable that the consumption varies between states and regions in choice of 
therapy and in amount of consumption, but comprehensive information on this matter 
is unavailable. In Europe, only Greece, France, Italy and probably Spain have higher 
consumption than USA.  
In Canada, the average consumption is approximately 10% lower (22,5 DID) than in 
the USA, although there are some data indicating regional differences. For example in 
British Columbia, the consumption was reduced from 19,5 DID in 1996 to 17,9 DID 
in 2000, clearly below the Canadian average (28).  
In Australia the average consumption declined from 24,8 DID in 1995 to just over 21 
DID in 2002 (38, 39). This reduction is possibly related to a national campaign 
promoting appropriate use of antibacterial agents against respiratory tract infections 
(39).  
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Interestingly, the number of active antibacterial substances available is lower in the 
USA compared to the European markets, 81 and 157, respectively.  
 
Europe 
The data for year 2003 show considerable variation in out-patient use of antibacterial 
agents in Europe with more than a 3-fold higher consumption in Greece with 31,4 
DID than in the Netherlands with 9,8 DID (26). There are also examples of rapid 
changes in consumption over short periods. For example, during the period from 2001 
to 2006 the consumption of antibacterial agents in Turkey more than doubled from 
14,6 DID to 31,4 DID, the largest increase taking place after the implementation of 
social insurance reform in 2005. In Turkey, 24% of the total annual expenditure for 
pharmaceuticals was spent on antibacterial agents in 2002. There is also a 
considerable variation in choice of therapy as the proportion of the consumption made 
up of cephalosporins, macrolides and quinolones is higher in southern Europe than in 
Scandinavia and other countries in northern Europe. The proportion of the 
consumption made up of narrow spectrum penicillins is higher in Scandinavia than in 
southern Europe (12, 25, 28, 36, 40-44). In the European markets there is an 
association between the numbers of antibacterial substances available for oral use and 
the consumption of these agents amongst outpatients (45). A high number of available 
substances correlated with a high level of consumption. 
 
The interpretation of sales data from some European low cost countries is highly 
complex because the high extent of parallel trade with exports to countries with higher 
medicine prices is poorly described. Based on data from wholesale only, the data for 
Greece include both national consumption and quantities for parallel export, and is 
therefore probably an overestimation of the actual use (12, 25).  
 
Although legislation in all European countries state that a patient in ambulatory care 
needs a prescription for antibacterial agents, it is well known that in some countries 
patients are allowed to buy antibacterial agents over the counter. If the national 
estimate on antibacterial use is based on reimbursement data, this will underestimate 
the true sale because there is no reimbursement on sales without prescription.  
The rate of self-medication in Europe varies between 1 and 220 per 1000 
inhabitants/year, but may be higher in certain populations. Rates are high in eastern- 
and southern Europe and low in western- and northern Europe. Sale of antibacterial 
agents without prescription over the counter in Spain represents up to 30% of the total 
consumption, and the most frequently used antibiotics for self-medication are broad 
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spectrum penicillins and macrolides (46-51). Data from other parts of the world also 
indicate frequent self-medication with antibiotics (52-54). 
 
For Europe, seasonal variations in the use of antibacterial agents with high 
consumption in the first and forth quarter of the year, is a well documented 
phenomenon related to increased incidence of respiratory tract infections. However, 
the seasonal variation is most excessive in high consuming countries (25, 55-59). As a 
high proportion of respiratory tract infections are self-limiting and of viral origin, a 
high versus a small mean difference in consumption between winter and summer 
months suggests inappropriate prescription practice or high level of self-medication 
(25). 
 
The Nordic countries 
Wholesale statistics on antibacterial agents for the Nordic countries is comprehensive. 
For the year 2007 the consumption (not counting metenamin) was lowest in Sweden 
(15,5 DID) and highest in Iceland (23 DID) (11). Other striking differences are the 
high relative consumption of quinolones in Finland and Sweden, the high relative 
consumption of cephalosporins in Finland, and the low consumption of tetracyclines 
in Denmark. Interestingly, tetracyclines are not reimbursed in ambulatory care in 
Denmark.   
The Norwegian Prescription Database covers all prescriptions collected at Norwegian 
pharmacies, and allows longitudinal studies on drug use in individuals (22). A study 
covering one year found the mean yearly population prevalence of antibacterial use to 
be 28% and 19%, for females and males, respectively (60). The choice of therapy 
differed between gender and age groups. Persons under 5 and over 75 years were high 
consumers. High consumers, defined as those using more than 60 DDD/year, 





4.3 Determinants for the consumption of antibacterial agents 
Health related behaviors are complex, and a discussion on the determinants for the 
consumption of antibacterial agents must take into consideration not only the 
perspective of the consumer, but also the perspective of the provider in addition to 
marketing and regulatory affairs (61). It is also necessary to distinguish between 
determinants characterizing use at individual or at societal level for use amongst 
outpatients, as well as determinants for use in hospitals or other facilities of 
institutional care. The contribution to the use of antibacterial agents from determinants 
at the individual and societal level amongst outpatients is probably not independent, 
and if possible both levels should be addressed simultaneously.  
 
Outpatients 
The majority of data on determinants for the use of antibacterial agents amongst 
outpatients originate from retrospective studies extracting data from patient records or 
from prospective studies collecting data via questionnaires or interviews from patients 
or physicians (33, 61-70). Studies extracting data from patient records often address a 
particular patient group, and this of course limits the external validity of the studies. 
However, these data are important as a fundament for building hypotheses when 
trying to explain the large differences in consumption and choice of therapy that, for 
example, are observed between European countries.  
 
Collecting data by sending questionnaires to a representative sample of a population is 
an attractive approach to gain information on determinants for the use of antibacterial 
agents, but the validity of the results is heavily dependent on the response rate. Studies 
collecting data from different European countries have documented considerable 
variation in response rate (61). 
 
At the national level, determinants for consumption of antibacterial agents amongst 
outpatients include the incidence and panorama of community acquired infections, 
culture- and social conditions, statutory practice, health care structures, spending 
power of the patients, level of self-medication, governmental regulations including 
market regulations and reimbursement policy, national guidelines and the number of 
different antibacterial substances marketed and trade names available (45, 61-64, 70, 
71). Possibly, national guidelines on treatment of common infectious diseases may 
have an important function as frameworks for local initiatives. There are a diversity of 
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promotional actions from the pharmaceutical industry, although their relative 
importance seems to be dependent on the type of drug (72). 
  
At the individual level, determinants for the consumption of antibacterial agents are 
availability of health care, spending power, level of self-medication, patient-doctor 
relations, marketing and knowledge about the effects and adverse effects of 
antimicrobial agents (63, 64, 73-76). The latter is exemplified by data from a study 
from the USA on misconceptions on prudent and appropriate use of antibacterial 
agents (77). Almost half of the interviewed patients were unaware of possible 
consequences of skipping doses and that antibacterial agents have no effect against 
viral infections. The providers stated that they prescribed antibacterial agents on 
patient demand. A majority of the patients were aware of resistance as a phenomenon, 
but only one-third considered resistance to be common.  
 
Similar trends were found in a study from Wales (78). Amongst patients, perceived 
importance and personal threat with regard to resistance were low, and less than 25 % 
of the respondents considered they could affect the threat of emerging resistance by 
correct use of antibacterial agents or to refrain from prescriptions. Another study, also 
from Wales, found that general practitioners were concerned about microbial 
resistance but infrequently faced problems with resistance in daily practice (79). Some 
of the respondents questioned the evidence linking their prescribing to possibly poorer 
future outcomes for their patients, and a few mentioned that increased awareness on 
resistance may enhance the use of second line empirical therapy.  
 
In a study from USA including generalists and infectious disease specialists, both 
groups preferred newer and broader spectrum agents against community acquired 
pneumonia compared to older agents still advised by national guidelines. The 
physicians rated the issue of possible contribution to the development of resistance 
lowest among seven determinants for their choice (80).  
 
In a Swedish study addressing the use of medical care and antibiotics amongst 
children aged 6-15 years, the investigators found that children of parents with less than 
10 years of education consumed less antibiotics than children of parents who had 
completed secondary school or longer education. They also found that children in 
rural areas consulted physicians more seldom and consumed less antibiotics compared 
to children in big cities (81). Due to the design of the study, it was impossible to 
explain the causal relationship behind these observations.  
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The above examples illustrate potential conflicts between balancing long-term societal 
and public health interests (reserving new and broad spectrum agents for severe 
infections and future use) and the short-term immediate interest of the individual 
(highest possible probability for cure).  
 
Hospitals 
The panorama of infectious diseases, local profile of bacterial resistance, the 
proportion of patients undergoing surgery and the proportion of total bed days spent in 
the intensive care unit are important determinants for the consumption of antibacterial 
agents in hospitals. Some concern has also been raised that downsizing of the nursing 
work force and interventions towards hospital restructuring may negatively affect 
patient risk for infectious diseases (82). In addition there are data indicating that 
university hospitals and increasing bed occupancy rates are associated with increased 
use of antibacterial agents. However, the data on the significance of hospital size on 
the consumption of antibiotics are conflicting (30, 32, 36, 83, 84).  
 
Supervisors are considered to be strong opinion leaders and are highly influential on 
choice of therapy, especially towards residents and inexperienced doctors. The role of 
other actors is less clear, but the availability of microbiologists and clinical 
pharmacists may be of importance (85). Some data indicate that the presence of 
infectious disease specialist or a multidisciplinary infectious disease team is important 
when making the decision on choice of therapy for severe infections (86). A hospital 
formulary on treatment of infectious diseases may have a major impact on antibiotic 
stewardship and in optimizing antibiotic therapy (87-91), although non-adherence to 
own guidelines is not uncommon (92). However, there are some concerns that a strict 
implementation of a hospital formulary may actually increase the evolution of 
resistant strains in a hospital due to high homogeneity in the choice of treatment (93-
95).  
 
Local guidelines may be more specific and adjusted to local therapeutic traditions, 
pattern of resistance and healthcare acquired infections on choice of therapy than 
national guidelines. However, local guidelines will meet the same barriers as national 
guidelines upon implementation in the hospital (85). A successful implementation of a 
local guideline depends on factors like distribution (easy access to electronic and 
paper versions), keeping the guidelines up to date, and a certain level of completeness 
on important diseases. Different medical disciplines have different priorities on the 
content of a guideline. Internal medicine residents want a high level of completeness, 
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while surgeons are more likely to appreciate conciseness and ease of use (85). The 
occurrence of non-adherence to local guidelines is well known, but the level is poorly 
described.  
 
The presence of restrictions on use of certain substances, systematic reassessment of 
treatment after 72 hours and nominative (pre-filled) delivery forms affects the choice 
and length of therapy, but not the decision whether to treat or not to treat (84, 96). 
Some studies have found computerized decision support systems (CDSS), when 
allowing for calibration to the local pattern of resistance, to prescribe appropriate 
empirical treatment significantly more frequent than physicians (97, 98). The 
treatment suggested by decision support systems lowered the length of hospital stay, 
lowered the total costs for antibacterial agents and diminished probable future costs 
due to lower future resistance. However, the role for CDSS is not unambiguous, and 
recent communications have raised questions on the safety of electronic prescribing 
systems as new types of errors may be introduced (99). Such errors include 
misconceptions through erroneous use of the software, automation and cognitive 
biases.  
 
Local impact and consequence of marketing from pharmaceutical industry is not well 
documented for the hospital setting, but there are some data indicating possible 
importance of marketing initiatives. An interesting example is the increase in the use 
of amoxicillin in combination with a beta-lactamase inhibitor in the Netherlands in the 
early 1990’s (101, 102). With poorly documented advantage over amoxicillin alone 
considering the profile of resistance in the Netherlands, the consumption of this 
combination increased three-fold within hospitals over a period of five years from 
1991, mostly due to increased use in prophylactic regimens and against respiratory 
tract infections. 
 
Although the impact of guidelines or formularies on the outcome of treatment of 
infectious diseases like urinary tract infections, community acquired pneumonia and 
skin and soft tissue infections is well documented, it is less clear whether such 
guidelines also affect the decision to treat or not to treat. This may be due to the fact 
that guidelines or formularies seldom give extensive support for diagnostic decisions.  
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4.4 Consumption of antibacterial agents and emergence of resistance 
Emergence of resistance to antibacterial agents is an unavoidable side-effect of 
consumption, and different types of data strongly support a causal relationship 
between consumption and the proportion of resistant bacterial strains at the individual 
level and at an aggregated level (4, 100-104). The evidence for this relationship builds 
on plausible biological explanations, concomitant variation, consistent associations 
over several studies, and demonstration of a dose – response relationship (105).  
 
The consumption of antibacterial agents is the major determinant for bacterial 
resistances in a defined ecological system like a hospital, but simultaneous influence 
from other factors are also of importance. Not taking into account confounding 
variables including non-adherence to infection control routines, use of other 
antibacterial agents than the one under study, low statistical power, complex bacterial 
population structures and dynamics and selection bias, may explain why some 
investigators have failed to establish a relationship between consumption and 
resistance (106).  
 
There is an abundance of studies addressing the correlation between the consumption 
of antibacterial agents and the level of resistance in a variety of bacterial species at the 
institutional level, although this is strictly no proof of a causal relationship. In 
addition, many studies describe a complex epidemiological situation with 
simultaneous efforts towards a reduction in consumption of certain antibacterial agents 
and intensified infection control efforts, making it difficult to attribute cause and effect 
to either measure.  
 
Fewer investigators have applied more sophisticated analytical methods such as 
multiple linear regression models or time series and transfer function modeling to 
investigate this relationship. In time series, consecutive observations are fitted to a 
mathematical model to predict future behavior of the series trying to explain its 
characteristics as well as the contributing factors. The method is valid when 
measurements are made at equal time intervals, and these intervals are much shorter 
than the study period. Transfer functions are an extension of this method that allows 
mathematical assessment of the relationship between one or several time series. The 
application of time series and transfer function modeling may give an estimate of the 
temporal relationship between consumption and resistance, take consumption of 
several antibacterial agents into account, and quantify the effect on resistance (106).  
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Unnecessary and extended use of broad spectrum antibacterial agents is associated 
with increasing levels of resistant strains (107-112). Traditionally the Scandinavian 
approach to treatment of infections has been quite conservative compared to other 
parts of the world. This has conserved the effect of old antibacterial agents where an 
initial conservative start of treatment has been followed by a switch to broad spectrum 
therapy for non-responders. Internationally, the concept of a conservative start of 
treatment and a subsequent change to broader spectrum therapy for non-responders 
has been challenged (113, 114). An alternative strategy involving initial broad 
spectrum therapy (carbapenems, cephalosporins, quinolones in monotherapy or in 
combination with others) and de-escalation (decreasing the number or the spectrum of 
the antibiotics, dose reduction, shorten the duration of treatment) accounting for the 
patient’s clinical response and microbial testing, is gaining momentum. For serious 
infections in geographic locations with high level of resistance this strategy has proven 
successful in reducing mortality and length of hospitalization (115, 116). However, the 
long time consequences on emergence and spread of resistance are not well known 
(117). 
 
Bacteria have developed a variety of mechanisms as protection against antibacterial 
agents, and some species have intrinsic resistance against single substances or classes 
of antibacterial agents (109). Bacteria acquire resistance either by spontaneous 
mutations or by horizontal gene transfer (conjugation, transformation or transduction), 
and the rate at which susceptible strains evolve or reacquire resistance decides the 
emergence of new resistant strains.  
 
The mechanism by which antibacterial agents select for resistance depends on the 
species. Treatment of tuberculosis is long lasting and bacterial resistance may evolve 
in the host by mutation. Choosing a treatment strategy that prevents development of 
resistance in the treated patient will also reduce the risk of spreading resistant strains 
to the community. For most other important human pathogens, rapid resistance 
development in the treated patient is a rare event, and resistance is mediated mainly by 
shift in the population structure, or horizontal transfer of resistance traits from other 
bacterial populations (102). For example one study identified an increase in resistance 
in Escherichia coli against commonly prescribed antibacterial agents during treatment, 
but a decline to baseline levels in less than two weeks after cessation of therapy (118). 
For some pathogens the relative use of certain broad spectrum agents both at the 
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individual and at an aggregated level is positively associated with increased risk of 
infection with a resistant strains (111).  
 
In pneumococci, oral penicillins promote resistance by increasing clearance of 
susceptible strains. In contrast, oral cephalosporins apparently increase the acquisition 
of new pneumococcal resistant strains during or shortly after treatment (119). Both 
mechanisms will contribute to the dissemination of resistant strains at the population 
level. Resistance in Streptococcus spp. against macrolides is acquired either via the 
mef gene, which encodes for an efflux pump mechanism, or via the erm genes which 
encode for modifications of the macrolide binding site at the bacterial ribosome (120). 
These mechanisms cause a high degree of resistance with erythromycin minimum 
inhibitory concentrations (MIC) of up to 512 mg/l. There are ecological data 
suggesting a link between consumption of antibacterial agents and resistance in 
Streptococcus pneumoniae (121, 122). High rates of resistance correlated to 
geographical areas with high consumption, and selective pressure on resistance 
expression via mef and erm genes has been documented for macrolides. A recent 
clinical trial with healthy volunteers assessed the effect of azithromycin and 
clarithromycin in promoting macrolide resistance in oral streptococci (123). Both 
treatments induced an increase in resistant pneumococci, and the increased level of 
resistance over the placebo group persisted for more than six months. Exposure to 
clarithromycin decreased the carriage of the mef gene and increased the carriage of the 
erm gene, and azithromycin doubled the MIC for erythromycin in streptococci that 
carried the mef gene. 
 
Sub inhibitory concentrations of quinolones modulate the expression of resistance 
determinants, specific adhesins and other virulence associated determinants in 
methicillin resistant Staphylococcus aureus (MRSA) (124). The potential of a strain to 
cause epidemics depends on extraordinary virulence in combination with efficient 
colonization and host-to-host transmissibility. The virulence is associated with the 
severity of disease, while colonization capacity and transmissibility may explain the 
capability of spread and persistence. The underlying molecular factors for these 
phenotypes may be entirely different (125).   
 
In summary, the level of bacterial resistance in human bacterial pathogens is 
positively associated with the selection pressure from different classes of antibacterial 
agents and the amount of consumption as a function of dose and time. Although the 
dynamics of the emergence of resistance is pathogen specific, it also depends on 
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different variables such as the biochemical mechanism conferring resistance, the 
genetic basis for the resistance, the antibacterial agent under consideration, bacterial 
mutation rates, mechanisms and frequencies of horizontal spread of resistance 
determinants between species and genera, shifts in bacterial population structures as a 
result of non-optimal treatment regimens, and the mechanisms of transmission and 
clonal spread of resistant strains as a function of lifestyle and culture (126). The 
transmission dynamics of resistant bacteria between outpatients are complex and in 
incompletely understood, but involve numerous individual- and population-level 
factors (4, 127). Although the impact of the use of antibacterial agents for resistance 
emergence is undisputed, a precise quantification of the risk factors involved remains 
to be achieved (128).  
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4.5 Interventions to change suboptimal usage of antibacterial agents  
There is a wide range of circumstances where consumption of antibacterial agents can 
be referred to as suboptimal. This includes misuse against infection of viral origin, 
excessive use of broad spectrum in stead of narrow spectrum antibacterial therapy, 
suboptimal dosage in relation to the pharmacodynamic- and the pharmacokinetic 
properties of the therapeutic agents, characteristics of the individual patient, untimely 
initiation of therapy, irrational choice of therapy in relation to the focus of the 
infection and knowledge of local ecology, and failure to initiating de-escalation in 
response to favorable microbial diagnostics or clinical response. Suboptimal 
consumption of antibacterial agents increases emergence of resistance, the risk of 
therapeutic failure and adverse reactions, and brings about unnecessary costs (75, 129-
132).  
 
When approaching the different aspects of suboptimal usage of antibacterial agents, 
interventions necessarily have to address a wide range of measures and take advantage 
of different designs. Numerous bodies have implemented a large number of 
interventions towards professionals or lay people using a variety of methods, alone or 
in concert, to improve suboptimal consumption of antibacterial agents both in the out-
patient setting and in hospitals. Mostly, these programs have been implemented at the 
national or the local level, but there are also some examples of international initiatives 
from The World Health Organization and the European Union (133). Some programs 
have been running for more than a decade, and changes in the consumption of targeted 
antibacterial agents are well documented (134, 135).  
 
Hospitals 
Although the consumption of antibacterial agents in hospitals only accounts for a 
small part of the total consumption, suboptimal use in hospitals is increasingly 
recognized to have serious consequences not only for the patients, but also for the 
pattern of resistance in common human pathogens outside the hospital (100). Despite 
huge efforts in education, development and implementation of national guidelines and 
local formularies, recent studies still suggest a substantial amount of inappropriate 
prescribing (136). It is obviously challenging to change attitudes, expectations and 
behavior on treatment of infectious diseases because the determinative factors for 
change in prescription practice depend heavily on the clinical setting and the location 
(85).  Thus, there is no single type of intervention that can be universally 
recommended (137).  
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Unfortunately, for a large proportion of the intervention initiatives, the true effects are 
poorly documented. This is mainly due to methodological flaws in the study design 
(96, 138), but there are also examples of studies with adequate design but with 
inappropriate choice of endpoints (96). Valid designs to study the effect of 
interventions are randomized clinical trials, controlled clinical trials, interrupted time 
series, time series, and controlled before and after studies.  
 
Outcome of interventions 
Most interventions aim to reduce the total consumption of antibacterial agents, to 
reduce the consumption of one or several broad spectrum agents, or to optimize the 
treatment regimens, but there are also a few examples of interventions that seek to 
increase the consumption of antibacterial agents (96, 138). The majority of the studies 
report outcomes on the consumption of the targeted agents, and some also report on 
clinical and microbiological outcomes. The results in the studies reporting clinical 
outcomes, mainly on mortality and readmission, are heterogeneous. In studies aiming 
to reduce the consumption of antibacterial agents, there are almost an even balance 
between studies reporting deterioration and improvement in clinical outcomes. The 
upper boundary of the confidence intervals suggests increased mortality risks (96). 
According to a recent Cochrane review, only a minority of the studies reporting effects 
on microbial outcomes provide convincing evidence that changes were caused by the 
intervention (29). This may in part be related to the method of how resistance is 
reported. Use of proportions of resistant isolates to assess the impact of the 
consumption of antibacterial agents instead of rates may be misleading, as proportions 
are dependent on both the susceptible and resistant bacterial populations while the 
incidence of resistance only depends on the resistant population (139). A French study 
that included data from 47 hospitals, found a stronger correlation between the 
consumption of antibacterial agents and the rate of MRSA and drug resistant 
Pseudomonas aeruginosa infections than between consumption and the proportion of 
resistance in these organisms (140). However, the cited Cochrane review only 
included studies published before 2004. Subsequent studies provide further evidence 
that reducing the consumption of quinolones and cephalosporins can reduce rates of 
MRSA and Clostridium difficile infections (95, 103, 141-145).  
 
Interventions aiming to reduce the consumption of a single antibacterial substance or 
restricting the use of a drug class will result in a shift towards other treatment 
strategies, which subsequently may lead to emergence of other resistance patterns. 
Increasing incidence of extended spectrum beta-lactamases (ESBL’s) in 
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Enterobacteriaceae following restrictions to the use of quinolones and replacement by 
cephalosporins or carbapenems have been highlighted by several authors, and 
restrictions to the use of cephalosporines have resulted in increased prevalence of 
carbapenem resistant Pseudomonas aeruginosa (144, 146, 147). However, a recent 
study covering 22 academic hospitals found that those hospitals restricting the use of 
carbapenems also used less quinolones than those with no restrictions. Restrictions in 
the use of carbapenemes were associated with lower incidence of resistance in 
Pseudomonas aeruginosa (148). Interestingly, these authors did not report on possible 
confounders such as infection control measures or the consumption of and resistance 
to cephalosporins. Information on concurrent switch of therapy to untargeted 
antibacterial agents is often scarce, and assessments of possible sustained effects on 
the pattern of resistance in common human pathogens after the termination of the 
projects are lacking.  
 
Heterogeneous use of antibacterial agents slows the emergence of resistance, and 
withdrawal of a class of antibacterial agents theoretically limits the selective pressure 
from these agents. This is the underlying principle for the introduction of antibiotic 
cycling (AC) as an option to reduce the emergence of resistance. AC is a scheduled 
substitution of a class of antibacterial agents with a different class with a comparable 
spectrum of activity. This substitution may be followed by any number new 
substitutions, but the original class must be reintroduced in order to complete the cycle 
(149). However, mathematical modeling indicates that AC will be inferior to 
combination therapy, mainly because combination therapy gives greater heterogeneity 
at the scale relevant to bacterial populations (93, 150). The few studies assessing the 
effect of AC on bacterial resistance, and which are not seriously hampered by 
methodological flaws, are inconclusive (149). 
 
Only a minority of the studies on interventions to promote prudent prescribing are 
multicenter studies. This raises concerns on the external validity of the studies. 
Furthermore, due to lack of standardization in design and choice of endpoints, it is 
difficult to perform a meta analysis on results from single hospital interventions (96).  
 
Outpatient setting 
Interventions to promote prudent prescribing of antibacterial agents in the out-patient 
setting have targeted inappropriate prescribing against viral infections, the choice of 
therapy and the interaction between the patient and the physician and physician and 
patient education (138). The intervention strategies can be categorized as physician 
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education alone, patient education alone, variants of physician and patient education 
combined, and physician and patient education with audit and feedback. Several 
studies have used strategies that target both patients and physicians. Valid study 
designs are considered to be the same as for interventions in hospitals (132).  
The majority of these studies address treatment of acute respiratory tract infections 
and report on outcomes on the rate of appropriate prescribing (proportion of patients 
receiving treatment, choice of therapy and length of treatment), the filling of delayed 
prescriptions, the incidence of colonization or infection with a resistant organism and 
the incidence of adverse effects (132, 138).  
 
Outcome of interventions 
A recent review identified 935 citations on interventions in ambulatory care of which 
165 were reviewed and 43 subsequently included in the review. Only 30 of these 
presented data that allowed quantitative analysis, but due to flaws in the reporting of 
the data it was impossible to perform a meta-analysis. The authors concluded that no 
single intervention strategy or combinations of strategies are clearly superior, but 
interventions targeting specific conditions or patient groups tend to have less impact 
on total use of antibacterial agents than interventions targeting broader patient groups 
(132). There was no statistically significant effect between active and passive 
educational strategies towards physicians, but this may be a consequence of low 
statistical power due the low number of included trials (n=10) and the heterogeneity 
between the trials. The slightly higher effects from active interventions compared to 
passive dissemination of information, and from interventions using mass media are 
promising but warrant further investigation. 
 
Another recent review on control strategies of the consumption of antibacterial agents 
in pediatric populations in hospitals and ambulatory care, included 28 studies of which 
six measured the impact of the intervention on microbial resistance (151). However, 
none of these six studies were performed in an ambulatory care setting. On the other 
hand, the lack of trials addressing this subject is not unexpected as mathematical 
modeling approaches suggest change in the consumption of antibacterial agents to 




The overall aim of the studies was to contribute to rational use of antibacterial agents.   
 
Acute otitis media (AOM) 
To contribute to prudent prescribing of antibacterial agents by examining whether 
educational efforts towards health care personnel and patients could reduce the 
proportion of patients with acute otitis media (AOM) receiving an antibiotic 
prescription, increase the relative use of penicillin V, and investigate to what extent 
the prescriptions against AOM were dispensed.  
 
Enterococcal isolates, susceptibility and consumption of antibacterial agents 
To contribute to optimal drug therapy of entrococcal infections by determining; i) the 
susceptibility of enterococcal species to commonly used antibacterial agents in a cross 
sectional collection of isolates from five Nordic hospitals, ii) to obtain information on 
the species distribution and population structure of resistance traits, iii) and by 
correlating enterococcal resistance to the usage of antibacterial agents in the same 
hospitals.  
 
Clostridium difficile associated diarrhea (CDAD) 
To describe the incidence of Clostridium difficile associated diarrhea (CDAD) at two 
university hospitals (Aker and Tromsø), and to investigate a possible association 
between CDAD and different hospital usage of broad spectrum antibacterial agents. 
 
Pharmacokinetics of netilmicin in neonates 
To contribute to optimal netilmicin treatment in neonates by validating a new 









We used a controlled before-and-after design to assess the impact of implementing 
national guidelines in combination with educational efforts towards health care 
personnel and parents on treatment of acute otitis media (AOM). The Emergency Call 
Service (ECS) in Tromsø was the intervention site, and the ECS in Harstad was the 
control site. 
 
Patients aged 1 to 15 years diagnosed with AOM were eligible for intervention. The 
criteria for the clinical diagnosis of AOM were acute ear-related symptoms (fever, 
otalgia, irritability) and signs of middle ear fluid (MEF), redness and bulging of the 
tympanic membrane, or perforation of the tympanic membrane and discharge of MEF. 
The baseline period was December 1997 to the end of March 1998, and the 
intervention period was December 1998 to the end of March 1999. 
 
We extracted relevant patient data, information on diagnosis, and choice of therapy 
with specially designed software from the patient administrative system at both sites. 
All data were encrypted using the MD 5 algorithm. Relevant dispensing data from the 
pharmacies in Tromsø were extracted and encrypted with the same algorithm.  
 
Categorical data were tested using the chi-squared (χ2) test. All tests were 2-sided, and 




We collected Enterococcal strains and consumption data on antibacterial agents from 
five tertiary care university hospitals in Denmark, Iceland, Norway and Sweden. Three 
groups of strains were included; i) all blood culture isolates from 1999; ii) consecutive 
clinically significant isolates from in-patients; iii) consecutive clinically significant 
isolates from outpatients. Groups ii) and iii) were collected over a 3-month period and 
contained maximum 40 strains from each hospital, and only the first isolate per patient 
was included.  
 
After speciation, all strains were screened for resistance to ampicillin, gentamicin and 
vancomycin by inoculation on specific agar plates. Isolates growing on any of the agar 
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media were further tested by E-test for the respective antibacterial agent, and the 
results were categorized according to NCCLS for susceptibility. Intermediately 
susceptible or resistant strains to vancomycin or teicoplanin were analyzed with PCR 
for vanA, vanB and vanC genes, and 13 E. faecium strains with reduced susceptibility 
to ampicillin were examined by pulse-field gel electrophoresis (PFGE) of SmaI 
chromosomal digests. We compared banding patterns visually and by the 
GelCompare® software package.  
 
National data on consumption of antibacterial agents were given as mean number of 
DDD/1000 inhabitants/day for the years 1997-99. Hospital consumption data were 
given as mean number of DDD/1000 bed days/year and as a mean proportion of total 
use in DDD for the years 1997-99. Hospital consumption data were based on sales 
from the respective hospital pharmacies. We used the 1999 version of the ATC system 
and DDDs, and all hospital data were aggregated to ATC main groups on the third or 




We collected information on local guidelines for treatment of infectious diseases, 
educational efforts and consultation visits during implementation of the guidelines, the 
consumption of antibacterial agents, the total number of and the proportion of positive 
C. difficile tests, the number of patients with antibiotic associated diarrhea (AAD) at 
four different points in time, bed occupancy rates, average length of stay, isolation 
rooms and other facilities for infection control, at two tertiary care university hospitals 
in Norway. All data concerned the year 2001. 
 
Hospital consumption data were based on sales from the respective hospital 
pharmacies, and were given as number of DDD/1000 bed days/year. Information on 
C. difficile tests was extracted from files at the respective microbial laboratories. Four 
point prevalence studies gave data on the proportion of patient receiving antibiotics, 
indication for treatment and the proportion of these patients with AAD. The 
Norwegian Research Unit provided data on bed occupancy for Hospitals (SINTEF-
UNIMED) and average length of stay from the respective hospitals. The infection 
control nurses recorded relevant infection control facilities.  
 
Categorical data were tested using the chi-squared (χ2) test. All tests were 2-sided, and 




We undertook an open, prospective non-comparative study in the neonatal intensive 
care unit at a tertiary care university hospital. All infants (n=129) less than 3 months 
without severe perinatal asphyxia, renal anomalies or known renal impairment and 
who received at least 3 doses of netilmicin were eligible over a period of 26 months 
form September 2000.  
 
Data collected included gestational age (GA), postnatal age (PA), postmenstrual age 
(PMA) (GA+PA), birth weight, complete blood count, blood cultures, C-reactive 
protein (CRP), and plasma creatinin (7,5 hours after the completion of the third dose). 
Susceptibility testing of invasive isolates was performed with the paper disc method 
and MIC for netilmicin was determined with E-test.  
 
Netilmicin 6 mg/kg was administered as an i.v. infusion over 30 min, and dosing 
intervals were set at 24 or 36 hours depending on GA, PA and PMA. All patients 
received ampicillin or cloxacillin in addition to netilmicin. Sample for through serum 
netilmicin concentration (SNC) was drawn just before the third dose (at 48 or 72 h). In 
addition, sample for SNC was drawn 0,5 h and 7,5 hours after the infusion of the third 
dose. The SNC was determined with a standard fluorescence polarization 
immunoassay. 
 
We calculated the elimination rate constant using a one-compartment first order 
model. Baseline data were given as mean values with standard deviation. Group 
differences were presented as mean values with standard error of the means. The 
Mann-Whitney U-test was used for intergroup comparisons, and a linear regression 










Småbrekke L, Berild D, Giæver A, Myrbakk T, Fuskevåg A, Ericson JU, Flægstad T, 
Olsvik Ø, Ringertz SH. Educational Intervention for Parents and Healthcare providers 
Leads to Reduced Antibiotic Use in Otitis Media. Scand J Infect Dis 2002; 34(9): 657-
9. 
 
The proportion of patients at the ECS in Tromsø receiving a prescription of antibiotics 
was reduced from 90% to 74%, and the proportion of prescriptions on penicillin V 
was increased from 72% to 85%. There were no statistically significant changes at the 
control site. There was no significant change in the age distribution of the patients 
diagnosed with AOM either in Tromsø or Harstad, but the age distribution of the 
patients receiving a prescription of antibiotics changed significantly in Tromsø in the 
study period. After intervention, a lower proportion of the two youngest age groups 
and a higher proportion of the oldest age group received a prescription. There was no 
change in Harstad. During the intervention there was a reduction in the proportion of 
patients diagnosed with AOM at the ECS in Tromsø, and no significant change in 
Harstad. The proportion of dispensed prescriptions was 70% both in the baseline and 
the study period. 
 
In conclusion, we found a reduced total consumption of antibiotics and a diminished 
use of broad-spectrum antibiotics for AOM in children aged 1 to 15 years attending 
emergency call service in Tromsø. Extraction of data on antibiotic use for AOM based 





Simonsen GS, Småbrekke L, Monnet DL, Sørensen TL, Møller JK, Kristinsson KG, 
Lagerqvist-Widt A, Torell E, Digranes A, Harthug S, Sundsfjord A. Prevalence of 
resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and 
Eterococcus faecium from clinical specimens and use of antimicrobials in five Nordic 
hospitals. J Antimicrob Chemother 2003; 51(2): 323-31. 
 
A total of 509 isolates were included in the study; 420 E. faecalis, 82 E. faecium, four 
E. gallinarum, two E. casseliflavus and one E. hirae. Among 156 blood culture 
isolates there were 104 E. faecalis, 49 E. faecium, two E. gallinarum and one E. 
casseliflavus. From the consecutive non-systemic isolates from in- and outpatients, 
84,2% and 95,3% were E. faecalis, respectively. The overall proportion of E. faecium 
from inpatients was 22,1%, and 4,1% from outpatients. E. faecium was more prevalent 
in blood culture (31,4%) than from non-systemic (14,1%) inpatient isolates.  
 
We did not find reduced susceptibility to ampicillin in E. faecalis, whereas resistance 
in isolates of E. faecium differed from 33,3% to 61,3% between hospitals. There was 
no difference between high level gentamicin resistance (HLGR) in E. faecalis isolates 
of in- and outpatients in either hospital, but HLGR prevalence was significantly higher 
in Bergen and Uppsala. HLGR in E. faecium was only detected in one hospital. PFGE 
typing of these strains showed two groups of four isolates with more than 80% 
identity.  
 
The mean yearly national consumption varied between 13,5 and 21,3 DDD/1000 
inhabitants/d in Denmark and Iceland, respectively, and there were large differences in 
yearly consumption of extended spectrum penicillins, glycopeptides and 
aminoglycosides. In the participating hospitals, the mean consumption of 
antimicrobials varied between 295 and 483 DDD/1000 bed-days/year, and there were 
large differences in the consumption of extended spectrum penicillins, cephalosporins, 
glycopeptides and aminoglycosides. 
 
The study confirmed a high proportion of E. faecium among hospital enterococcal 
isolates with an average of 31,4% in blood cultures and 14,1% in the non-systemic 
isolates. The data indicated an overall low prevalence of resistance. All E. faecalis 
isolates were susceptible to ampicillin, but we found large differences of HLGR 
between hospitals, although Nordic countries generally report low prevalence in 
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enterococci. Almost half of the E. faecium isolates were resistant to ampicillin and 
aminoglycosides. There was a cluster of HLGR isolates from one hospital, and many 
of these isolates were also resistant to gentamicin. Some of the isolates were clonal. 
 
There was a factor of 1,6 in difference in overall use between the hospital with the 
lowest and the highest consumption, and there was also a difference in the pattern of 
antimicrobial agents being used. Although the cluster of ampicillin resistant/HLGR E. 
faecium was found in the hospital with the highest consumption of extended spectrum 
penicillins and aminoglycosides, this was not sufficient to establish a causal 
relationship. The study did not contain sufficient data for analysis of the dynamic 
relationship between antimicrobial use and occurrence of resistant bacteria. 
 
In conclusion, the study documented low use of antibacterial agents and low level of 
resistance in E. faecalis and E. faecium in Norway compared to other regions of 
Europe and the USA. The large differences between hospitals in the amount of use, 
choice of therapy, and in the prevalence of resistance, indicated a potential for further 
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Clostridium difficile infections related to antibiotic use and infection control facilities 
in two university hospitals. J Hosp Infect 2003; 54: 202-6. 
 
Total consumption of antibiotics was on the same level for both hospitals (47 – 60 
DDD/100 hospital days/year), but the pattern of use was different. The use of broad 
spectrum penicillins was threefold higher at Aker, while especially the use of 
cephalosporins, clindamycin and carbapenems was higher in Tromsø. Despite the 
reduction in use of broad spectrum antibiotics at Aker, the incidence of CDAD 
increased and was higher than in Tromsø until 2001. There was no significant change 
in diagnostic policies for CDAD in either hospital. Data from the point prevalence 
studies showed no difference between the hospitals in the proportion of patients 
receiving antibiotics, or in the proportion of patient with AAD. Single rooms, isolation 
rooms and other facilities for infection control were more available in Tromsø, but the 
bed occupancy rate was higher and the duration of hospital stay was longer at Aker.  
 
The results indicated that the incidence of CDAD depended not only on amount and 
pattern of antibiotic use, but also on infection control facilities and clinical factors. 
Our data were insufficient to determine the impact from the specific factors on the 
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netilmicin dosage regimen in infants. Scand J Infect Dis 2004; 36(6-7): 474-9. 
 
Aminoglycosides exhibit concentration dependent bactericidal and postantibiotic 
effects. High peak concentrations, at least 8 to 10 times the minimal inhibitory 
concentration (MIC), are associated with improved therapeutic outcome in life-
threatening bacterial infections in adults. Plasma concentrations above 2 mg/L shortly 
before the next dose are associated with increased risk of oto- and nephrotoxicity.  
 
In 110 infants, during first week of life (mean gestational age (GA) 35,5 – range 24 to 
42 weeks), the mean plasma concentration 30 minutes (Cp 0,5 h) after completing the 
infusion  was 10,5 mg/l. The mean Cp 0,5 h was significantly lower (9,0 mg/l) in 38 
infants with post natal age over 7 days. Fourteen of 15 infants with Cpmin >2 mg/l had 
GA <28 weeks. During the first week of life, we found significant correlations 
between GA and elimination half-life of netilmicin, and between plasma creatinine 
and elevated Cpmin. There was no correlation between Cp 0,5 h and GA. 
 
This dosing regimen yielded Cp 0,5 h above 8 mg/L in 88 % of all treatment courses. 
In the first week of life, a dosing interval of 48 h for infants of GA <29 weeks, 36 h 
for infants of GA 29 to 36 weeks and 24 h for full term babies seem appropriate to 







Immediate initiation of an effective drug treatment against the causative agent(s) in a 
serious bacterial infection is associated with a favorable outcome for the patient and 
reduced treatment costs. However, this approach must be balanced against possible 
adverse drug reactions and unfavorable ecological effects. The widespread and 
unnecessary use of broad spectrum antibacterial agents exerts a continuous selective 
pressure on bacteria and accelerates the emergence and spread of resistance. The 
substantial consumption of antibacterial agents due to inappropriate treatment against 
self limiting infections contributes to the unnecessary emergence and persistence of 
resistant pathogens (114). 
8.1 Acute otitis media  
Well designed clinical trials over the last two decades have shown only moderate 
effects of antibacterial therapy against uncomplicated AOM for children older than 6-
12 months (153). It is increasingly recognized that antibiotic treatment is not 
necessary for all cases of AOM. However, internationally there are still clinical 
guidelines advocating liberal use of antibiotics on this indication, and clinical practice 
is highly inconsistent and frequently non-compliant to restrictive guidelines (154). It is 
highly questionable whether further research should aim to elaborate possible minor 
benefits from antibacterial treatment on this indication. A better theoretical 
understanding on how to optimize organizational settings, provider and patient 
behaviors and patient expectation in connection to this indication would be valuable 
(155). Furthermore, there are undoubtedly some patients benefitting from treatment, 
and measures to better identify this cohort are required.  
 
The extent of treatment and choice of therapy 
Pre-intervention, approximately 90% of those diagnosed with AOM at the ECS in 
Tromsø received treatment with antibacterial agents (156). This is around 20 
percentage points higher than was found in a study from general practice in southern 
Norway (157). Our data does not explain this difference, but they probably reflect 
different patient populations and a more liberal treatment strategy because follow up 
of the patients are more challenging in the ECS setting. During the intervention, 74% 
of the AOM patients at the ECS in Tromsø received a prescription on antibacterial 
treatment, but only 70% of the prescriptions were dispensed at the pharmacy. The 
proportion of dispensed prescriptions was the same in the baseline and the study 
periods. We are not aware of other studies providing information to which extent the 
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prescriptions on AOM are dispensed. Our data suggest that approximately 50% of the 
patients during the intervention period received treatment, a proportion which still is 
considerable higher than for example in the Netherlands.  
 
Interestingly, epidemiological data document lower incidence of mastoididtis, a 
serious complication to AOM, in the USA compared to the Netherlands and the 
Scandinavian countries (158). Considering that more than 95% of children below 15 
years receive antibiotics against AOM in the USA, a rate reduction of mastoiditis of 
approximately 2/100 000 persons/year has to be weighted against increased risk of 
adverse reactions and emergence of bacterial resistance. A recent study from Iceland 
found increased incidence of mastoiditis in children under 18 years in a period when 
the consumption of antibacterial agents was reduced (159). The incidence in the adult 
population was unchanged. Among the children with mastoiditis, 80% had been 
diagnosed with AOM, and 72% of these patients had received antibacterial treatment. 
However, the authors used sales figures of fluid antibacterial agents as an 
approximation for the consumption of antibacterial agents in this cohort. The validity 
of this approximation was not assessed, but the long period of observation is to some 
extent reassuring. In summary, the above discussion provides no proof of causality 
between a high rate of antibiotic treatment and a reduced risk of mastoiditis, but 
highlights that intervention studies may lack the statistical power to identify infrequent 
adverse complications and calls for continuous assessment of the incidence of 
mastoiditis. 
 
Our data suggest good compliance to Norwegian guidelines on choice of therapy. We 
found that 85% of the AOM patients during the intervention period received a 
prescription on phenoxymethylpenicillin (PenV). This observation apparently 
contrasts the study by Straand et al, in which 58% of patients with ear infections 
received PenV, but the study by Straand covered all age groups. In addition, “ear 
infections” also covers external otitis where the choice of therapy is different.  
 
In a recent Swedish study, 192 children aged 2 to 16 years with symptoms of AOM 
lasting less than four days and with no perforation, were randomized to treatment with 
PenV or no treatment with antibacterial agents (160). The median recovery time was 4 
days in each group, but the group receiving PenV used significantly less analgesics. 
There were no differences in the proportion of patients with middle ear effusions or 
perforations at the final control after three months. These results need to be confirmed, 
but they suggest a limited effect of PenV in certain patient populations. A recent meta-
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analysis found a statistically significant effect on persistence of symptoms after 2 to 4 
days from antibiotic treatment of AOM, but questioned the clinical relevance of the 
small incremental effect seen, considering the increased risk for adverse outcomes 
(153). The authors also highlight the possible public health benefit from limiting 
antibiotic use against AOM, and the increased individual risk for colonization with 
resistant strains. 
 
Interventions – methodological challenges 
Numerous intervention studies covering major disciplines in health care have been 
published, but there is still a lack of evidence to support decisions about which designs 
and strategies are likely to be optimal in the presence of various implementation 
barriers under different circumstances. No relationship was found between the number 
of components and the effects of multifaceted interventions or the type of intervention, 
but some data indicate better effect in settings where the potential for improvement is 
high (132, 155).  
 
Flaws in the design of the intervention can hamper the possibility to accurately 
estimate the efficiency of guideline dissemination and the implementation strategies. 
Uncontrolled trials, before and after studies, and time series with few pre-intervention 
data points are prone to bias and confounding. Secular trends, cyclical patterns like 
seasonal trends, random fluctuations with no discernible pattern, short time 
interventions and autocorrelation are serious threats to correct estimates of 
intervention effect (96, 132, 155). Controlled before and after studies suffer additional 
threats from the Hawthorne effect and contamination. The Hawthorne effect is a 
phenomenon that occurs when individuals alter their performance or behavior due to 
the awareness that they are being studied or observed (161).  The change may be 
positive or negative depending on the situation. A special variant of the Hawthorne 
effect occurs when the members of the control group alter their behavior when they 
realize they are in the control group.  
 
Contamination occurs when ingredients in active interventions are transportable and 
difficult to confine. This imposes a risk for dissemination of elements of the 
intervention to the non-intervention site, resulting in bias, reduced power and an 
underestimation of the magnitude of effect. The risk of contamination increases when 
the intervention is aimed at professionals, if the intervention is desirable, and if there 
is some kind of interaction between subjects in the two groups. Contamination and its 
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effects have only been quantified in a few studies using a randomized controlled 
design (155).  
 
Some of the methodological challenges concerning the evaluation of the effect of 
interventions can be overcome by adequate design. If the effect of an intervention is 
investigated in only two study sites, the use of interrupted time series (ITS) will 
probably increase the validity of the results. In ITS data are collected at several time 
points before and after the intervention. This protects against artifacts due to secular- 
or seasonal trends, and is also informative on the sustainability of the intervention. If 
several study sites are analyzed, randomized controlled trials (RCT) should be 
considered as this design gives the strongest possible protection against bias and 
confounding.  
 
Interventions - national campaigns 
There are examples of national campaigns addressing prudent use of antibacterial 
agents from several European countries, the USA, Canada, several Asian countries 
and Australia (133, 162, 163). These campaigns have been multifaceted including 
regulatory measurements like drug licensing, drug access and reimbursement in 
combination with intervention towards health care professionals and consumers. 
Initiatives towards health care professionals have focused on improved diagnosis 
through use of rapid diagnostic tests, guidelines on prudent prescribing, practice 
profiling and feedback, educational programs and use of delayed prescriptions. 
Consumer interventions have been educational in nature, and the most successful 
initiatives have taken advantage of broad programs including television advertising, 
printed matter, presentations in schools and day-care centers, and information sharing 
on web-sites (126). However, there are insufficient data on the absolute effects and the 
sustainability of the different types of interventions available (132, 138). Further 
studies are also warranted to establish the optimal balance in interventions between 
education and empowerment versus restriction, and how to take maximum advantage 
of media activity.  
 
Interventions - local initiatives in the outpatient setting 
Interventions in the out-patient setting have addressed inappropriate use of 
antibacterial agents for viral infections, choice of therapy for various indications, and 
the duration of treatment for respiratory tract infections (138). Didactic lectures, 
printed educational materials for health care personnel or audit and feedback alone 
usually have produced none or only modest effects on prescribing. Delayed 
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prescriptions for self-limiting infections or for infections which immediate treatment 
may be postponed, have reduced the consumption of bacterial agents apparently 
without increasing morbidity. Educational strategies addressing physicians, patients 
and the public through various channels have successfully reduced prescribing of 
antibacterial agents on inappropriate indications (138), and change in reimbursement 
has changed the choice of therapy for respiratory tract infections (43, 164, 165).  
There are only a few examples of studies on the effects of interventions on bacterial 
resistance, and studies with adequate control for bias and confounding are scarce. A 
Cochrane review identified four studies with sound methodology. Only one study 
from Finland documented a sustained reduction in the level of resistance group A 
streptococci in association with the intervention (166).  
 
Intervention at the Emergency Call Service (ECS) in Tromsø 
A previous study documented a high turnover of children with acute otitis media 
(AOM) during the winter months, and high rates of antibiotic treatment of AOM 
combined with a low rate of treatment with narrow spectrum penicillin at the ECS in 
Tromsø (156).  On this basis, we judged the ECS in Tromsø to be a relevant location 
for an intervention aiming to implement national guidelines on treatment of AOM. 
 
There was a discrepancy between an ideal design for the intervention, and what was 
possible to carry through at the study site. We were, for example, unable to hire extra 
personnel that would have enabled us to follow up patients who refrained from a visit 
to the doctor after receiving the folder which described information on symptomatic 
treatment. Such information would have been valuable to determine to what degree 
these patients postponed their consultation at the ECS for a later consultation by the 
family doctor. Data were also insufficient for a satisfactory cost evaluation, not only 
concerning the costs for planning and implementation of the intervention, but also for 
possible costs from changes in clinical practice.  
There were no data available on local or national incidence of AOM in the baseline 
period or in the study period. It is well documented that the incidence of some 
infectious diseases changes over time, but how this affects the total consumption of 
antibacterial agents is not straight forward because diagnostic routines, treatment 
strategy, and the proportion of patients receiving treatment may change over time 
(167).  
 
Data from USA over the period 1996 to 2005 give conflicting numbers on the 
proportion of children with AOM receiving treatment with antibacterial agents. One 
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study using retrospective data from emergency departments found an increase in the 
proportion of children up to 12 years receiving treatment (168). Another study 
focusing on children younger than two years enrolled in private insurance plans 
covered more than 40 000 persons yearly during the period from 1997 to 2004. Using 
the period from 1997 to 1999 as baseline, the investigators found a 43% decrease in 
the rate of visits due to AOM, and a 42% decrease in the rate of prescriptions in 2004 
(169). Similar results were found in another study addressing the change in the rate of 
antibiotic prescribing in children younger than 18 years. The investigators studied the 
claims for dispensed medications and physician visits in 9 health plans in the USA 
from 1996 to 2000 (170), and found that reduction in rate of antibiotic prescribing 
differed over age groups, but was on average approximately 25%. A concurrent 
reduction in the rate of diagnosis of AOM accounted for half of this reduction, and the 
investigators speculate that public campaigns and media attention has contributed to 
changes in diagnostic thresholds for possible viral infections.  
 
A similar trend was found in the UK (171). In a retrospective study on data from 108 
general practices covering on average a population of approximately 642 700 persons 
between 1994 to 2000, the investigators found that the standardized consultation rate 
for respiratory tract infections (RTI) fell by 35% to 273 per 1000 registered patients 
per year. The proportion of consultations where patients received a prescription for an 
antibacterial agent fell from 79% to 67%. The authors concluded that the reduction in 
prescribing against respiratory tract infections was a result of fewer persons visiting 
the general practitioner for such infections, and a lower proportion of those diagnosed 
with RTI receiving treatment with antibacterial agents. 
 
In a recent study from Kalmar County in the south-east part of Sweden, the 
investigators followed all patients (n=146454) attending 23 of the 32 health care 
centers in the county from June 1999 to the end of 2005 (59). During this period, 
RTI’s were diagnosed in 240 447 consultations. There was a significant reduction in 
the number of consultations for AOM, acute tonsillitis, laryngitis, and pharyngitis, but 
the proportion of patients receiving a prescription (44% to 46%) for an antibacterial 
agent was constant. The reduction was most evident for AOM and acute tonsillitis. 
There was no change in the rate of consultations for common cold, acute sinusitis, 
influenza and lower respiratory tract infections. New national guidelines in Sweden 
for the treatment for AOM and sore throat were launched in year 2000 and 2001, 
respectively. However, the investigators found no change in choice of the treatment 
for AOM until the season 2003 - 2004. The change in the treatment for AOM 
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coincided with a randomized controlled trial on the treatment for AOM in Kalmar 
County. It is unclear whether the change came as a result of a late implementation of 
the national guidelines or in connection to an information program launched as a part 
of the randomized trial.  
 
Similar observations are made for other infectious diseases. Assessing national trends 
in ambulatory visits for skin and soft tissue infections in the USA, the investigators 
found a 50% increase in the rate of visits from 1997 to 2004 (172). Prescriptions 
recommended for community acquired MRSA infection increased 4-fold in the same 
period. Another research group also published similar results although that study only 
included patients who attended emergency departments in hospitals (173). 
 
Due to the controlled before and after design, our intervention study is therefore prone 
to secular trends on the incidence of AOM or other forms of bias introducing 
systematic changes in the attendance of patients to the ECS, changes in diagnostic 
practice, or choice of therapy. The risk for bias could have been reduced by including 
data from at least three pre-intervention points, preferably from the same winter 
periods over the three previous years. We cannot rule out that Hawthorne effects or 
contamination have contributed to the results in our study. Hawthorne effects would 
increase the apparent effect of the intervention, while contamination would drive the 
results toward the null.  
 
8.2 Enterococcal resistance to ampicillin, gentamicin and vancomycin and use 
of antimicrobials in five Nordic hospitals 
The selection pressure from antibacterial agents at the hospital can be seen as a 
combination of the total amount of use within a hospital or a department over a time 
period, the profile and characteristics of the antibacterials used, the proportion of 
patients receiving treatment, and the number of treated patients. Obviously, there is no 
single variable that can capture all necessary information to accurately describe all 
aspects of drug usage.  
 
Our study included 509 enterococcal isolates from five Nordic tertiary care university 
hospitals, and yearly national and hospital specific data on consumption of 
antibacterial agents. The number of isolates was limited, and the results should be 
interpreted with caution. However, the prevalence of resistance against ampicillin and 
gentamicin varied between the five hospitals, highlighting the need for local 
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surveillance. Due to the cross-sectional design, our study could not give information 
on the incidence of enterococcal infections, but documented the distribution of 
enterococcal species in three different groups of isolates.  
The high proportion of E. faecium in hospital blood stream isolates is in accordance 
with other studies. Longitudinal data indicate an increasing incidence of enterococcal 
infections in tertiary care teaching hospitals, and an increasing incidence of infections 
with E. faecium (174, 175). This is worrisome, because a high proportion of E. 
faecium strains are resistant to ampicillin, and more than half of the strains resistant to 
ampicillin are also resistant to gentamicin. Empiric therapy for an enterococcal 
infection with ampicillin and gentamicin will thus carry a high risk for therapeutic 
failure. In addition to clonal spread of resistant strains, there is possibly also an 
association between the increasing incidence of E. faecium blood stream infections 
and an increasing consumption of broad spectrum antibacterial agents, changes in the 
hospital patient populations, or changes in the hygienic measures. 
  
Data on hospital consumption of antibacterial agents at the five hospitals were given 
by the respective hospital pharmacies as mean over three years and adjusted to 
hospital bed days. This is a crude measure, and unsuitable for capturing short time 
variations in consumption and possible temporal relationships to the incidence of 
resistant strains. No data on consumption of antibacterial agents at patient level were 
available. 
 
A parallel analysis of individual and aggregated data on exposure for antibacterial 
agents and resistance in Gram-negative bacilli found divergent results (23). The 
authors observed a minimal change in bacterial resistance at hospital level despite 
substantial increase in the consumption of third generation cephalosporins, 
quinolones, ampicillin-sulbactam, or decrease in the consumption of imepenem. At 
individual level, consumption of cephalosporins, quinolones, ampicillin-sulbactam, or 
imepenem was a significant risk factor for resistance. However, the effect of exposure 
at an individual level may also wane as a result of an interaction between an individual 
and a group effect (23).  
 
Alternatively, it is possible to adjust the consumption of antibacterial agents to the 
number of new patients to the hospital. Several investigations on the linkage between 
the consumption of antimicrobials and resistance have adjusted to bed days, but it is 
unknown which denominator will give the best prediction of this relationship (23). 
This is probably of no importance in our study, but should be investigated in further 
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studies on models describing the temporal relationship between consumption of 
antimicrobial agents and resistance. For some antibacterial agents, DOT may be an 
alternative to DDD, but a serious limitation is that DOT does not distinguish between 
a low or high daily prescribed dose (16, 176). 
 
The association between antibacterial consumption and resistance  
In Norway, transferable vancomycin resistance is so far not established in clinical 
enterococcal isolates (15). This contrasts the situation in other parts of Europe and the 
USA and in oher parts of the world where vancomycin resistant enterococci (VRE) 
have become endemic in hospitals. The nosocomial epidemiology of vancomycin 
resistant enterococci (VRE) has been extensively studied. However, to what extent the 
consumption of different broad spectrum- and anaerobic antibacterial agents increase 
the risk of colonization or infection with VRE remains unclear (177, 178). The 
emergence and spread of VRE in hospitals depends on several mechanisms including 
the exposure to antibacterial agents and to VRE reservoirs, and host factors related to 
colonization and infection. Although the exposure to different classes of antibacterial 
agents has been addressed in several studies, there have been controversies on which 
and to what extent different agents contribute to the emergence and spread of VRE 
(178). There have also been conflicting data between individual level studies and 
population level studies, possibly due to methodological flaws.  
 
The epidemiology of enterococci in hospitals is complex, and the methodological 
approach to investigate the relationship between exposure to antibacterial agents and 
the proportion of VRE must take into account interactions between different 
antibacterial agents, dosage, the temporal relationship between consumption and the 
emergence of resistance, and the fact that the observations of resistance and 
consumption are dependent. In a study from Greece using time series and transfer 
function models, the investigators found that the bimonthly incidence of VRE per 
1000 patient days could be predicted by the incidence of VRE the two previous 
months, and the consumption of extended spectrum cephalosporins, quinolones, 
glycopeptides and beta-lactam-beta-lactamase inhibitors. There was a positive 
correlation between the incidence of VRE and the consumption of cephalosporins, 
quinolones, and glycopeptides with a delay of two, two, and four months respectively, 
and a negative correlation with the consumption of beta-lactam-beta-lactamase 
inhibitors (178).  
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Interestingly, restrictive interventions on the consumption of glycopeptides and broad 
spectrum cephalosporins, at the population level, have not uniformly contributed to 
limit the emergence and spread of VRE, and the sustainability of successful 
interventions is poorly documented (177, 179). None of the previous studies referred 
to are randomized controlled trials (RCT), but on the other hand, RCT are probably 
not a suitable design to answer the question on possible association between the 
consumption of an antibacterial agent and the emergence of a specific resistance 
mechanism. Several of the studies carry a substantial risk for bias due to a before and 
after design with the control group from the same hospital. In addition, there is 
apparently no consensus on the definition of outbreaks versus endemicity that further 
increases the risk of time effects. Possibly, a comprehensive review of restrictive 
interventions also carries a high risk for publication bias (177). Further elucidation of 
a possible causal association between consumption of different classes of antibacterial 
agents and emerging resistance in Enterococcus spp. should be addressed in 
prospective multi-centre studies taking advantage of longitudinal data on resistance, 
consumption of antibacterial agents and analyze data using time series and transfer 
function modeling. Other variables like hygienic measures, length of stay, underlying 
diseases and the prevalence of resistance amongst out-patients should be accounted for 
as the emergence of resistance rarely is mono-specific (179). In addition, possible 
contribution from factors like the rate of re-acquisition, reduced fitness costs for 
strains carrying resistance determinants, directional selection of genetically linked 
traits and the stability of extra chromosomal elements carrying resistance determinants 
should be accounted for (5).  
 
The association between consumption of antibacterial agents and resistance in 
other bacterial pathogens 
There is a salutary theoretical foundation for a correlation between increase in use of 
antibacterial agents and the subsequent increase in the prevalence of resistant bacteria. 
Correspondingly, there is a theoretical framework supporting the assumption that a 
reduction in consumption of antibacterial agents should reduce resistance, but data 
from observational studies using ecological data on regional or national level are 
conflicting. Some studies investigating exposure to beta-lactams or macrolides and the 
risk of colonization or infection with resistant Streptococcus pneumoniae or 
Streptococcus pyogenes, have shown geographical correlations and quantitative 
relationships between consumption of beta-lactams, macrolides and resistance (56, 
166, 180-182). Data from the United Kingdom (UK) and Northern Ireland showed an 
increasing trend in penicillin resistance in pneumococci up to 1997, but a decreasing 
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trend from 1999. UK pharmacy sales of oral macrolides and beta-lactams fell by 
approximately 30% in the late 1990s following a growing concern on problems with 
resistant strains. The fall in sales of macrolides was not associated with any decline in 
macrolide resistance (181). 
 
An ecological study using national data on consumption and national surveillance data 
from published studies covering 20 European countries, found strong correlation 
between streptococcal resistance and antibacterial selection pressure from penicillins 
and macrolides on national level (183). A study from USA found that variations in 
resistance of S. pneumoniae were better explained by geographic variations in 
consumption of antibacterial agents than by spread of clones with certain serotypes. 
This was reflected by differences in the proportions of resistance within a particular 
serotype, rather than by the differences in the frequencies between serotypes harboring 
resistance (184).  
 
Other investigators have been unable to show an impact on resistance of pneumococci 
or carriage of resistant pneumococci following a decline in the consumption of 
macrolides and beta-lactams (129, 134, 185). A study on sulphonamide resistant E. 
coli showed a 6% increase in the proportion of resistant strains following a 98% 
reduction in the use of sulphonamides over a period of 8 years (186). Five years later, 
a follow up study found sulphonamide resistance to persist undiminished (187). These 
contrasting observations suggest that other factors than antibacterial drug consumption 
is important contributors to preserve the level of resistance. 
 
Applying time series and transfer functions to study the correlation between 
ceftazidime consumption and the percentage of resistant or intermediately susceptible 
Gram-negative bacilli, the investigators found the percentage of resistance to be a 
function of the percentage of resistance three and five months before, and the hospital 
ceftazidime use the previous month (188). Applying the same methods, the same 
investigators found similar correlations between imepenem usage and the percentage 
of resistant or intermediately susceptible P. aeruginosa strains. 
 
Analyzing the dynamic relationship between monthly percentage of MRSA and 
hospital use of several antibacterial agents, a time series model including previous 
monthly percentage of MRSA, and consumption of macrolides, third-generation 
cephalosporins and quinolones as independent variables explained more than 90% of 
the monthly variation in prevalence of MRSA (103). An alternative model excluding 
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the monthly consumption of antibacterial agents explained approximately 81% of the 
monthly variation in the prevalence of MRSA.  
 
Using a multiple linear regression model, no correlation was found between the 
percentage of resistance in Gram-negative bacilli and gentamicin consumption the 
same year (189). Changing the model and using the gentamicin consumption data 
from the previous year gave a significant correlation to the percentage of resistance. 
Other researchers have built linear regression models including the consumption of 
several antimicrobial agents and in addition defining a coupling fraction which 
describes the percentage of isolates resistant to an antibacterial agent that is also 
resistant to another agent (190). These models relying on several antimicrobial agents 
gave better correlation between consumption and percentage of resistance than models 
only taking one antimicrobial agent into account (191). 
 
In summary, we documented the distribution of enterococcal species in three different 
groups of isolates. The high proportion of E. faecium in blood stream isolates is in 
concordance with other studies. Between the five hospitals, the consumption of 
antibacterial agents expressed as DDD/1000 bed days/year varied by a factor of 1,6, 
and we also documented diverging prevalence of enterococcal resistance against 
ampicillin and gentamicin between the hospitals. Our data were insufficient to 
establish a causal relationship between consumption and resistance, but highlighted 
the need for local surveillance.  
 
Other considerations 
The Antibiotic Centre for Primary Care (Antibiotikasenteret for primærmedisin) was 
established in Norway in 2006 as publicly financed project. The main tasks for the 
Centre are to initiate and support relevant research in primary health care, to develop 
guidelines and post graduate courses for physicians in primary health care and to 
develop relevant public information on the use of antibiotics (192).  
 
There is yet no analogous body to address similar issues in hospital health care. 
However, a document on national strategies suggests to clarify the need for a centre 
covering hospital and other institutional health care (193). The establishment of a 
national body covering these tasks is highly desirable considering that hospitals are 
important locations for emergence and spread of resistant bacterial strains. In addition 
there is a lack of clinical trials addressing the treatment of important infectious 
diseases accounting for the low level of resistance in Scandinavia and the Netherlands 
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compared to most other parts of the world. Possibly, a national body could contribute 
to the initiation and support of this type of public health research. 
 
All Norwegian hospitals are required to establish guidelines on treatment of infectious 
diseases (194). To my knowledge there has been no systematic evaluation on quality 
and implementation of local guidelines, nor has there been a critical appraisal of all 
costs involved. It is also highly questionable whether there is a need for local 
guidelines in hospitals in Norway considering that there are no major regional 
differences in the pattern of resistance amongst common human pathogens. Possibly, 
there should be more focus on implementation and compliance to national guidelines, 
and on coordination of multi-centre research to answer important clinical questions.  
 
8.3 Clostridium difficile associated diarrhea in two university hospitals 
Prudent prescribing of antibacterial agents to hospital inpatients reduces the cost of 
therapy, the risk of emerging bacterial resistance, and the risk of adverse side effects 
including the risk for Clostridium difficile associated diarrhea (CDAD) (96).  
During the first years CDAD was acknowledged to exist, the most common cause of 
CDAD was thought to be previous exposure to clindamycin. A common approach to 
the affected patients was withdrawal of clindamycin and oral treatment with 
vancomycin. A majority of the patients had good clinical response, but up to 25% 
relapsed when ceasing vancomycin (195). Increasingly, broad spectrum 
cephalosporins and penicillins with beta-lactamase inhibitors were recognized as 
inducing agents, and lately C-8-methoxy substituted fluoroquinolones have also come 
into focus (196). Several other patient characteristics like underlying disease, previous 
hospitalization, age and use of other medication are identified as risk factors for 
hospital acquired CDAD (197). In addition several institutional characteristics like 
previous incidence of CDAD and infection control measures should also be accounted 
for (145, 198). Recent data strongly suggest a weaker association between the 
consumption of broad spectrum antibiotics and CDAD in connection with a low 
compared to a high hospital incidence of Clostridium difficile infections (196, 198). In 
addition, several underlying characteristics of the link between consumption of 
antibiotics and CDAD, including the timeframe for environmental contamination, 
colonization of patients, subsequent exposure to antibiotics, development of infection, 
and diagnosis of disease, highlight the need to account for the temporal relationships 
between several input variables and the emergence of CDAD (145, 198).  
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There are major concerns about study design in studies assessing consumption of 
antibacterial agents and hospital acquired CDAD (199). Several examples of 
methodological flaws due to bias and confounding, choice of inappropriate control 
groups, misclassification, not accounting for underlying diseases and lack of precision 
in effect estimates due to insufficient sample size limit the identification and impact of 
different risk factors for CDAD. Especially, in case-control studies the choice of 
control group deserves careful attention (200, 201). Cases and controls should come 
from the same source population, which means that the controls would have been 
included amongst the cases if they had developed the disease. Restricting the selection 
of controls to those suspected to have CD invalidates the assumption that the controls 
are representative for the population from which the cases arose, and enhances the risk 
that the exposures are similar for all causes of hospital acquired diarrhea or because of 
misclassification of patients with false negative tests as controls (199). Either case 
enhances the risk for a biased result towards the null.   
 
Undoubtedly, the association between the consumption of antibacterial agents and 
hospital acquired CDAC are complex and inputs from different variables may be 
difficult to interpret. Indeed, the exposure to broad spectrum antibacterial agents is 
probably of great importance, but the relative contribution from different classes of 
antibiotics and their temporal effects has yet to be determined.  
 
The epidemiology of CDAD has changed over the last decade. There is evidence 
suggesting an increasing incidence of hospital related CDAD (202-204), and data from 
the USA shows an increase in CDAD associated mortality rate from 5,7/million 
population in 1999 to 23,7/million in 2004. Indeed, there is also evidence that the 
disease is becoming more refractory to treatment. The change in incidence, the 
severity of the disease and the refractoriness to treatment are associated to the 
emergence of a hyper virulent strain (195). Reports on outbreaks caused by this strain 
have come from a large number of hospitals in Northern America and from hospitals 
in several countries in Europe. In Norway there has so far only been sporadic isolates 
of this strain (Gunnar Skov Simonsen, personal communication). 
 
In addition to increasing risk for a prolonged stay at the hospital and a serious 
outcome of hospitalization, a high incidence of CDAD constitutes a considerable 
economic burden to the hospital. In Europe, the incremental cost of CDAD is 
estimated to be in the order of 5 to 15000 euro per case (204). If the hyper virulent 
strain NAP1/BII/027 becomes endemic, the average cost per case will further increase. 
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In summary, our study compared data on antibiotic use, infection control facilities and 
the incidence of CDAD at two tertiary care university hospitals. There are obvious 
differences between the hospitals considering the patient population, bed occupancy 
rate, proportion of single rooms, other infection control facilities and choice of 
antibacterial therapy. Compliance to hand hygienic policies and use of alcohol based 
hand scrubs were not measured, but a possible effect from alcohol based hand scrubs 
on the incidence of CDAD is nevertheless uncertain (145). Although we found a lower 
consumption of broad spectrum antibacterial agents at Aker University hospital, the 
incidence of CDAD was higher at Aker University Hospital than at the University 
Hospital of North Norway in Tromsø. This observation highlights the importance of 
other variables in facilitating the acquisition and spread of CDAD. Another interesting 
aspect is that our data did not allow accounting for possible temporal relationships 
between relevant risk factors and the incidence of CDAD. There is a time lag between 
an increase in the consumption of certain broad spectrum antibacterial agents and an 
increasing incidence of CDAD, and the incidence of CDAD is also dependent upon 
the incidence of CDAD the previous months (145, 198). 
 
8.4 Validation of a simplified netilmicin dosage regimens in infants 
Streamlining of therapy has received increasing attention in institutional care although 
this is only a systematic application of professional, persuasive, restrictive and 
structural interventions. Streamlining may imply use of rapid diagnostic tests, 
targeting of therapy after identification of the probable causative agent, dose 
adjustment after therapeutic drug monitoring or to renal function, and dose tapering 
during treatment.  
 
Aminoglycosides express high efficacy towards a wide range of human bacterial 
pathogens, and in vitro studies have demonstrated a concentration dependent 
bactericidal- and post antibiotic effect. Treatment with aminoglycosides implies an 
increased risk of oto- and renal toxicity to the patient regardless of single or multiple 
daily dosing regimens, and therapeutic drug monitoring is mandatory. Interestingly, 
multiple daily dosing of aminoglycosides was universally adopted in both adults and 
children based on no evidence (205).  
 
A maximum plasma concentration / MIC ratio of 8-10 has been demonstrated to 
improve therapeutic outcome in life threatening bacterial infections in adults, 
 51
minimize bacterial pathogen survival and reduce emergence of resistance. Meta-
analyses have documented favorable efficacy, less toxicity, and reduced costs of once-
daily dosing regimens versus three times daily regimens in adults (6). Similar 
conclusions are drawn in two meta-analyses addressing high-dosage extended interval 
regimens in neonates and children (205, 206), although the incidence of irreversible 
ototoxicity in children after once-daily dosing is unknown (205). In fact, no adequate 
long term assessment of the incidence of hearing impairment has yet been reported in 
studies using extended interval dosing (207).  
 
All aminoglycosides are eliminated renally, and an immature renal function or a renal 
dysfunction due to tubular damage will decrease renal clearance and increase 
elimination half-life. The pathogenesis of aminoglycoside nephrotoxicity is directly 
related to the accumulation of drug within the renal cortex (208), although an affection 
of the tubular function may occur earlier (209). Nephrotoxicity assessed by elevated 
levels of creatinin is rare in high dose extended interval regimens, and seldom occurs 
early in the treatment of neonates (210, 211). Accounting for the limited number of 
patients (n=11) with plasma creatinin >90 μmol/l in our study, the observation of an 
association between creatinin levels >90 μmol/l and an increased risk of trough 
concentration above 2 mg/l should be interpreted with caution. Most of these patients 
had immature renal functions, and the design of the study did not allow for an 
assessment of causality between elevated creatinin, netilmicin treatment and other risk 
factors. A recent study using retinal binding protein and alpha-1-microglobilin as 
indication of tubular damage and dysfunction, found similar and low rates of 
nephrotoxicity in once-daily dosing as compared to multiple daily dosing in neonates 
with a GA below 37 weeks (212). 
 
Bacterial sepsis in preterm neonates is a serious complication commonly treated with a 
combination of an aminoglycoside and a beta-lactam agent (213). Due to increased 
extracellular volume and immature renal function in preterm neonates, it is difficult to 
achieve adequate maximum concentration in combination with a safe through 
concentration within a 24 hour dosing interval in this patient group. Some authors 
have argued that extended intervals may increase the risk of exceeding the duration of 
the post antibiotic effect and thereby impose a risk for prolonged periods of clinically 
inadequate drug concentrations, although a clear therapeutic range, and the correlation 




Gestational age (GA) and the volume of distribution correlate, but despite keeping the 
dosage at 6 mg/kg body weight we found no correlation between GA and peak 
concentration during the first week of life. On the other hand, we found the half-life to 
be inversely correlated to postnatal age during the first week of life. Assessing 
pharmacokinetic parameters on the first day of life in preterm neonates, Rengelhausen 
et al. found that systemic clearance and volume of distribution (not normalized to 
body weight) significantly correlated to birth weight, but not to GA. In a study of 
amikacin, Allegaert et al found no change in volume of distribution in a cohort of 
neonates with GA of 24 to 30 weeks on the first day of life. Since both cohorts only 
included neonates on their first day of life, the authors were precluded to assess 
postnatal changes in volume of distribution and possible consequences for the 
elimination half-life. However, clearance approximately doubled from a GA of 24 
weeks compared to infants with a GA of 30 weeks (214, 215). On assessing the 
population parameter variability for clearance with and without covariates, these 
authors found a lower variability when covariates like body weight and GA were 
accounted for. Still, approximately 35% of the variability in clearance was 
unexplained suggesting important impact of other variables (215).  
 
The dosing interval in our study was 24 or 36 hours depending on gestational age, 
postnal age, and post menstrual age.  In the group with PA 0 to 7 days, and GA <34 
weeks, 15/35 patients had a Cmin >2 mg/l, strongly suggesting that the 36 hours dosing 
interval was too short. In a study assessing the elimination of a single dose of 5 mg/kg 
the first day of life, estimated time to the next dose was 42 hours (213). We found a 
significant correlation between elimination half-life and GA, but our data also indicate 
considerable inter-individual variation. This is in accordance with data from other 
investigators, and probably suggests a limited predictability of aminoglycoside 
pharmacokinetics in preterm neonates.  
 
In summary, a high-dosage netilmicin dosage regimen with a dosing interval of 48 
hours for neonates with gestational age (GA) < 29 week, 36 hours for GA 29 – 36 
weeks and 24 hours for full term babies will avoid the majority of trough levels over 2 
mg/l, and still provide adequate therapeutic efficacy. 
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9 Further aspects 
 
As outlined in this thesis, there are shortcomings in existing methods for monitoring and 
optimizing the use of antibacterial agents. There are also numerous limitations in the 
understanding of the complex temporal relationship between drug consumption and the 
emergence of antimicrobial resistance. Below I suggest possible contributions to the identification 
of causual relations within the field of pharmacoepidemiology of antimicrobials. 
 
Antibacterial agents and interventions  
 
• Standardization of methods.  
• Include variables on costs, clinical- and microbial outcomes. 
• Assess the sustainability of the interventions.  
 
Antibacterial agents and resistance 
 
• Standardization of methods. 
• Further development of methods for investigation of temporal relationships 
between consumption and resistance. This includes theoretical modeling on the 
impact of the prevalence of resistant strains, individual versus ecological data, to 
investigate the significance of applying different adjusting factors in the models.  
• Well designed multi-centre studies addressing important clinical question, for 
example on treatment of community acquired pneumonia.  
• Increase focus on clinical and microbial outcomes when implementing 
interventions. 
 
Antibacterial agents and neonates 
 
• To validate the efficacy of antibacterial dosing regimens for neonates.  
 
Antibacterial agents and Clostridium difficile associated diarrhea 
 
• Apply established epidemiological principles when planning future studies. This 
includes recruiting an adequate sample size, to control for bias and confounding 
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